40 results about "Esophageal adenocarcinoma" patented technology

Probe sets and methods of using probes and probe sets for selectively detecting high grade dysplasia and esophageal adenocarcinoma or low grade dysplasia from biologic samples are described. Methods of the invention include contacting a biological sample obtained from a subject with a set of chromosomal probes to selectively detect an esophageal carcinoma or precursor lesion in the sample, if any, under conditions for specifically hybridizing the probes to their nucleic targets present in the sample. The presence or absence of high grade dysplasia and esophageal adenocarcinoma or low grade dysplasia is thereafter specifically determined from the hybridization pattern detected for the set of chromosomal probes to the biological sample.

There is disclosed a diagnostic or prognostic assay for cancer, particularly gastrointestinal and esophageal adenocarcinoma. Specifically, the present invention provides a methylation pattern that can be assayed by standard methylation assays of CpG islands, including which genes are hypermethylated and which genes are unmethylated in gastrointestinal and esophageal adenocarcinomas, Barrett's esophagus, and normal squamous mucosa.

Methods and composition for tumor therapy, especially esophageal adenocarcinoma (EAC), are described. For example, in certain aspects methods for determining Hedgehog and mTOR signaling pathway status to select patients for administering a combination therapy of Hedgehog and mTOR signaling inhibitors are described. Furthermore, the invention provides compositions that involve testing kits for determining signaling status.

Methods for the detection and screening of esophageal adenocarcinoma (EAC) patients and for the monitoring of EAC treatment using a panel or panels of small molecule metabolite biomarkers are disclosed. In other aspects, methods for detection and screening for the progression of high-risk conditions (BE and HOD) to EAC and to monitoring treatment using a panel or panels of small molecule metabolite biomarkers are disclosed. The biomarkers are sensitive and specific for the detection of EAC, and can also be used to classify Barrett's esophagus (BE) and high-grade dysplasia (HOD), which are widely regarded as precursors of EAC.

Results of studies of nucleosides in biofluid specimens from patients with esophageal adenocarcinoma and related disorders have identified five biomarkers of the conditions: 1-methyladenosine, N²,N²-dimethylguanosine, N²-methylguanosine, cytidine and uridine. In certain embodiments, methods of measuring these biomarkers and kits for measuring these biomarkers are provided.

The invention relates to a esophageal cancer prognosis biological marker and a detection method and an application thereof, wherein the biological marker is RNA binding protein TRA2A, and the amino acid sequence is shown in SEQ ID NO: 1; the DNA sequence is shown in SEQ ID NO: 2. The detection method of the esophageal cancer prognostic biological marker mainly comprises two detection methods whichare an mRNA expression change detection and an mRNA expression change detection combined with a gene mutation detection. The detected samples comprise tissues and organs. The biological marker can beused for preparing esophageal cancer diagnostic reagent and/or medicine. The esophageal cancer prognostic biological marker can commonly be used for two main esophageal cancers which are the esophageal adenocarcinoma and the esophageal squamous cell carcinoma, and the detection of the esophageal cancer prognostic biological marker is convenient and rapid, the experiment process is simple and theresult is clear. Except the TRA2A primer, the used reagents are mostly common reagents and the cost is low.

The inventors have determined, contrary to the prior art and experience, how to successfully use triciribine to treat esophogeal adenocarcinoma by one or a combination of (i) administering triciribine only to patients which according to a diagnostic test described below, exhibit enhanced sensitivity to the drug; (ii) use of a described dosage level that minimizes the toxicity of the drug but yet still exhibits efficacy; or (iii) use of a described dosage regimen that minimizes the toxicity of the drug.

This invention relates, e.g., to methods for predicting a subject's risk for developing esophageal adenocarcinoma (EAC) or high-grade dysplasia (HGD), comprising determining in a sample from the subject the methylation levels of transcriptional promoter regions of various combinations of, among other genes, (a) cadherin 13, H-cadherin (heart) (CDH13); (b) tachykinin-1 (TAC1); (c) nel-like 1 (NELL1); (d) A-kinase anchoring protein 12 (AKAP12); (e) somatostatin (SST); (f) transmembrane protein with EGF-like and two follistatin-like domains (HPP1); (g) CDKN2a, cyclin-dependent kinase inhibitor 2a (p16); or (h) runt-related transcription factor 3 (RUNX3).

To determine appropriate treatment doses of cold atmospheric plasma (CAP), the Canady Helios Cold Plasma Scalpel was tested across numerous cancer cell types including renal adenocarcinoma, colorectal carcinoma, pancreatic adenocarcinoma, ovarian adenocarcinoma, and esophageal adenocarcinoma. Various CAP doses were tested consisting of both high (3 L/min) and low (1 L/min) helium flow rates, several power settings, and a range of treatment times up to 5 minutes. The impact of cold plasma on the reduction of viability was consistently dose dependent, however the anti-cancer capability varied significantly between cell lines. While the lowest effective dose varied from cell line to cell line, in each case an 80-99% reduction in viability was achievable 48 hours after CAP treatment. Therefore, it is critical to select the appropriate CAP dose necessary for treating a specific cancer cell type.

In some embodiments, a method for aiding assessment of the likelihood of dysplasia or esophageal adenocarcinoma being present in a subject can include (a) providing an esophagal sample from said subject (b) determining the methylation status of (i) SLC22A18, (ii) PIGR, (iii) GJA12 and (iv) RIN2 in said sample wherein if 2 or more of said genes are methylated then an increased likelihood of presence of dysplasia or esophageal is determined. The invention also relates to apparatus for same.

The invention relates to a biomarker for esophageal cancer typing and application thereof, and relates to the technical field of medical detection. The biomarker comprises at least five kinds of genes such as GAS7, LRP1B, MAP2K4, FOXP1, WWOX and the like. When the biomarkers are used for carrying out typing diagnosis on esophageal squamous carcinoma and esophageal adenocarcinoma, the diagnostic power AUC can reach 0.9447 when 5 markers are used, the diagnostic power AUC can reach 0.9789 when 10 markers are used, the diagnostic power AUC can reach 0.9714 when 20 markers are used, and the diagnostic power AUC can reach 0.9489 when all the markers are used, so that the biomarkers have excellent diagnostic power and can be used for diagnosis of esophageal squamous carcinoma and esophageal adenocarcinoma. The invention provides a method for discriminating two pathological subtypes based on molecular level, provides mutual verification for pathological diagnosis results, ensures that the case diagnosis results are correct, and is convenient for subsequent precise treatment.

The invention belongs to the field of biomedicine, and particularly relates to a marker for predicting response of an esophageal adenocarcinoma patient to combined treatment and application thereof. The combined treatment provided by the invention is neoadjuvant radiotherapy and chemotherapy combined with attezumab treatment. In particular, the marker includes RORB, IGKV19, FGD5P1, or a combination thereof.

The invention provides an application of combined pyroptosis related genes to an esophageal adenocarcinoma prognosis model. The combined pyroptosis related genes are CASP1, GSDMB, IL1B, PYCARD and ZBP1. An establishment method of the esophageal adenocarcinoma prognosis model comprises the following steps: step 1, collecting and sorting data; step 2, screening differentially expressed pyroptosis related genes; step 3, reanalyzing the differentially expressed pyroptosis related genes; step 4, establishing a risk index evaluation model; and step 5, constructing an alignment diagram. The prognosis model provided by the invention has the advantage of high accuracy, and can provide a new method for disease diagnosis and prognosis for esophageal adenocarcinoma patients clinically.